Indication

FOSRENOL is indicated to reduce serum phosphate in patients with end stage renal disease.

Important Safety Information

FOSRENOL is contraindicated in patients with bowel obstruction, ileus, and fecal impaction.

Confidence in our support program

Dealing with hyperphosphatemia can be overwhelming for your patients with end stage renal disease (ESRD). And you can't be with them all the time. That's why we created the FOSRENOL On Track™ Support Program, a support program that reinforces your efforts and provides them materials that may help manage their condition.

Help your patients get On Track with our support program.

Access+
Financial resources to help qualified patients get On Track.
Everyday Support+
Support and education to help your patients.
Resources+
Tools at your clinic to help patients manage their treatment plan.

Enroll Now

Help your patients get started with FOSRENOL On Track™

Shire Cares: Patient Assistance & Support Program. Learn More

Indication

FOSRENOL is indicated to reduce serum phosphate in patients with end stage renal disease.

Important Safety Information

FOSRENOL is contraindicated in patients with bowel obstruction, ileus, and fecal impaction.
Serious cases of gastrointestinal obstruction, ileus, and fecal impaction have been associated with lanthanum use, some requiring surgery or hospitalization. Risk factors include altered gastrointestinal anatomy, hypomotility disorders, and concomitant medications.
Advise patients to chew or crush the tablet completely to reduce the risk of adverse gastrointestinal events. Advise patients with poor dentition that they may crush tablets completely. Advise patients to take FOSRENOL with or immediately after meals.
Patients with acute peptic ulcer, ulcerative colitis, Crohn's disease, or bowel obstruction were not included in FOSRENOL clinical studies.
FOSRENOL has radio-opaque properties and may give the appearance typical of an imaging agent during abdominal X-ray procedures.
The most common reactions seen with FOSRENOL in clinical trials included nausea, vomiting, diarrhea, and abdominal pain.
There is potential for FOSRENOL to interact with (1) compounds that bind to cationic antacids (ie, aluminum-, magnesium-, or calcium-based agents), (2) oral quinolone antibiotics, and (3) thyroid replacement medication; therefore, such concomitant medications should be dosed separately from FOSRENOL to avoid drug interactions. See specific dosing recommendations in the full Prescribing Information.
No adequate and well-controlled studies have been conducted in pregnant women and pediatric patients. FOSRENOL is not recommended for use during pregnancy.
The safety of lanthanum carbonate excreted in human milk is unknown. Caution should be exercised when FOSRENOL is administered to a nursing woman.
The use of FOSRENOL in the pediatric population is not recommended.

Please see Full Prescribing Information.

©2011 Shire US Inc., Wayne, PA 19087 1-800-828-2088
FOS-01491 12/11
FOSRENOL On Track™ is a trademark of Shire LLC.
FOSRENOL^® is registered with the US Patent and Trademark Office

All content of this website including text, images, graphics, sound files, and their arrangement, belongs to Shire and is protected by international copyright laws. All other intellectual property rights are reserved. The content may not be copied for commercial use or distribution, nor may these objects be downloaded, modified, or posted to other sites.

This site is intended solely for US residents and is governed solely by US laws and government regulations. Please see our privacy policy for more information. While Shire US Inc. makes reasonable efforts to include accurate, up-to-date information on the site, Shire US Inc. makes no warranties or representations as to its accuracy. Shire US Inc. assumes no liability for any errors or omissions in the content of the site.

The site you are accessing is maintained by a third party over whom Shire has no control. Shire does not review, approve, or necessarily endorse viewpoints, inferences, or conclusions stated in or implied by the content of this site.

Shire is not responsible for third-party content or the consequences of your use thereof.

Do you wish to continue?

YES NO